2,840 Matching Annotations
  1. Jun 2020
    1. 2020-05-21

    2. The number of deaths occurring in the COVID-19 treatment centre that MSF runs in Aden, Yemen, speaks to a wider catastrophe unfolding in the city. The UN and donor states need to do more urgently to help the response.  
    3. Catastrophe unfolding in Aden’s only COVID-19 treatment centre
    1. 2020-06-04

    2. A Washington Post survey of the nation’s 50 wealthiest people and families, who have a collective net worth of nearly $1.6 trillion, found that their public donations amount to about $1 billion. (Victoria Adams Fogg/The Washington Post/Photo illustration. Bill Gates by Elaine Thompson/AP; Carl Icahn by Neilson Barnard/Getty; Jeff Bezos by Patrick Semansky/AP; Mark Zuckerberg by Mark Lennihan/AP)
    3. The pandemic is testing the generosity of billionaires, according to a Washington Post survey of the 50 richest Americans
    1. 2020-06-04

    2. Smithsonian teams up with the World Health Organization to educate on COVID-19. Working through seven tasks helps young people learn about coronavirus and investigate ways to stay safe. Plan centers on critical reasoning, investigating and questioning. Analytical thinking and creativity are in-demand skills, according to the Forum’s Future of Jobs Report.
    3. How the world's largest museum is encouraging kids to come up with their own COVID-19 action plan
    1. 2020-05-05

    2. Evidence indicates markedly higher mortality risk from COVID-19 among Black, Asian and Minority Ethnic (BAME) groups, but deaths are not consistent across BAME groups. Similarly, adverse outcomes are seen for BAME patients in intensive care units and amongst medical staff and Health and Care Workers. The exact reasons for this increased risk and vulnerability from COVID-19 in BAME populations are not known. There may be a number of contributing factors in the general population such as overrepresentation of BAME populations in lower socio-economic groups, multi-family and multi-generational households, co-morbidity exposure risks, and disproportionate employment in lower band key worker roles. For Health and Care workers, there are increased health and care setting exposure risks.
    3. BAME COVID-19 DEATHS – What do we know? Rapid Data & Evidence Review
    1. 2020-05-29

    2. COVID-19 poses an extraordinary threat to global public health and an effective vaccine could provide a key means of overcoming this crisis. Human challenge studies involve the intentional infection of research participants and can accelerate or improve vaccine development by rapidly providing estimates of vaccine safety and efficacy. Human challenge studies of low virulence coronaviruses have been done in the past and human challenge studies with severe acute respiratory syndrome coronavirus 2 have been proposed. These studies of coronaviruses could provide considerable benefits to public health; for instance, by improving and accelerating vaccine development. However, human challenge studies of severe acute respiratory syndrome coronavirus 2 in particular might be controversial, in part, for ethical reasons. The ethical issues raised by such studies thus warrant early consideration involving, for example, broad consultation with the community. This Personal View provides preliminary analyses of relevant ethical considerations regarding human challenge studies of severe acute respiratory syndrome coronavirus 2, including the potential benefits to public health and to participants, the risks and uncertainty for participants, and the third-party risks (ie, to research staff and the wider community). We argue that these human challenge studies can reasonably be considered ethically acceptable insofar as such studies are accepted internationally and by the communities in which they are done, can realistically be expected to accelerate or improve vaccine development, have considerable potential to directly benefit participants, are designed to limit and minimise risks to participants, and are done with strict infection control measures to limit and reduce third-party risks.
    3. 10.1016/S1473-3099(20)30438-2
    4. COVID-19 human challenge studies: ethical issues
    1. 2020-05-26

    2. The United Nations Development agency has warned that coronavirus could reverse human development for the first time in 30 years. The fall-out from the pandemic is expected to hit poorer economies harder, as they're less able to deal with the socio-economic impacts of the virus. COVID-19 has forced the closure of millions of schools worldwide, preventing children form receiving a proper education.
    3. Pandemic may reverse human development for first time in 30 years, UN says
    1. 2020-05-22

    2. 10.1016/S0140-6736(20)31180-6
    3. BackgroundHydroxychloroquine or chloroquine, often in combination with a second-generation macrolide, are being widely used for treatment of COVID-19, despite no conclusive evidence of their benefit. Although generally safe when used for approved indications such as autoimmune disease or malaria, the safety and benefit of these treatment regimens are poorly evaluated in COVID-19.MethodsWe did a multinational registry analysis of the use of hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19. The registry comprised data from 671 hospitals in six continents. We included patients hospitalised between Dec 20, 2019, and April 14, 2020, with a positive laboratory finding for SARS-CoV-2. Patients who received one of the treatments of interest within 48 h of diagnosis were included in one of four treatment groups (chloroquine alone, chloroquine with a macrolide, hydroxychloroquine alone, or hydroxychloroquine with a macrolide), and patients who received none of these treatments formed the control group. Patients for whom one of the treatments of interest was initiated more than 48 h after diagnosis or while they were on mechanical ventilation, as well as patients who received remdesivir, were excluded. The main outcomes of interest were in-hospital mortality and the occurrence of de-novo ventricular arrhythmias (non-sustained or sustained ventricular tachycardia or ventricular fibrillation).Findings96 032 patients (mean age 53·8 years, 46·3% women) with COVID-19 were hospitalised during the study period and met the inclusion criteria. Of these, 14 888 patients were in the treatment groups (1868 received chloroquine, 3783 received chloroquine with a macrolide, 3016 received hydroxychloroquine, and 6221 received hydroxychloroquine with a macrolide) and 81 144 patients were in the control group. 10 698 (11·1%) patients died in hospital. After controlling for multiple confounding factors (age, sex, race or ethnicity, body-mass index, underlying cardiovascular disease and its risk factors, diabetes, underlying lung disease, smoking, immunosuppressed condition, and baseline disease severity), when compared with mortality in the control group (9·3%), hydroxychloroquine (18·0%; hazard ratio 1·335, 95% CI 1·223–1·457), hydroxychloroquine with a macrolide (23·8%; 1·447, 1·368–1·531), chloroquine (16·4%; 1·365, 1·218–1·531), and chloroquine with a macrolide (22·2%; 1·368, 1·273–1·469) were each independently associated with an increased risk of in-hospital mortality. Compared with the control group (0·3%), hydroxychloroquine (6·1%; 2·369, 1·935–2·900), hydroxychloroquine with a macrolide (8·1%; 5·106, 4·106–5·983), chloroquine (4·3%; 3·561, 2·760–4·596), and chloroquine with a macrolide (6·5%; 4·011, 3·344–4·812) were independently associated with an increased risk of de-novo ventricular arrhythmia during hospitalisation.InterpretationWe were unable to confirm a benefit of hydroxychloroquine or chloroquine, when used alone or with a macrolide, on in-hospital outcomes for COVID-19. Each of these drug regimens was associated with decreased in-hospital survival and an increased frequency of ventricular arrhythmias when used for treatment of COVID-19.FundingWilliam Harvey Distinguished Chair in Advanced Cardiovascular Medicine at Brigham and Women's Hospital.
    4. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis
    1. 2020-06-01

    2. 10.31234/osf.io/jkmut
    3. Exploring the effects of the COVID-19 pandemic on the mental health of adolescents is urgently needed. The aim of this study was to develop and validate a Japanese-version Fear of COVID-19 Scale (FCV-19S) among adolescents. Japanese adolescents administered the Japanese-version FCV-19S, Generalized Anxiety Disorder 7-item scale (GAD-7), Patient Health Questionnaire for Adolescents (PHQ-A), and Perceived Vulnerability to Disease Scale (PVDS). Statistical analyses revealed that the Japanese-version FCV-19S has a two-factor model consisting of an emotional-responses and physiological-responses factor, as well as high reliability (emotional: α = .71; physiological: α = .82). Constructive validity was shown by the significant positive correlation between the GAD-7 and emotional (r = .11) and physiological response (r = .25), between PHQ-A and physiological response (r = .19), and between both factors and the PVDS subscale (rs > .16). These results indicate that the Japanese-version FCV-19S has a high internal consistency and moderately good construct validity.
    4. Development and validation of the Japanese version Fear of COVID-19 Scale among adolescents.
  2. May 2020
    1. 2020-04-17

    2. European leaders have called for green investment to restart growth after the coronavirus pandemic. A group of 180 political decision-makers, business leaders, trade unions, campaign groups and think tanks have urged the bloc to adopt green stimulus measures. The EU is headed for a steep recession triggered by the outbreak, but is divided on how to finance economic recovery. EU leaders are due to meet next week to discuss the recovery plan, which would look to promote biodiversity and rebuild stronger economies.
    3. The EU looks towards green coronavirus recovery
    1. 2020-05-22

    2. COVID-19 is making the interconnectedness of our world clear. The pandemic may be laying the groundwork for the efforts required to tackle climate change. These changes will need political and industrial leadership, as well as global collaboration.
    3. Climate action must stay top of the global agenda as we emerge from COVID-19
    1. 2020-05-15

    2. As COVID-19 is rapidly spreading across the globe, short-term modeling forecasts provide time-critical information for decisions on containment and mitigation strategies. A major challenge for short-term forecasts is the assessment of key epidemiological parameters and how they change when first interventions show an effect. By combining an established epidemiological model with Bayesian inference, we analyze the time dependence of the effective growth rate of new infections. Focusing on COVID-19 spread in Germany, we detect change points in the effective growth rate that correlate well with the times of publicly announced interventions. Thereby, we can quantify the effect of interventions, and we can incorporate the corresponding change points into forecasts of future scenarios and case numbers. Our code is freely available and can be readily adapted to any country or region.
    3. 10.1126/science.abb9789
    4. Inferring change points in the spread of COVID-19 reveals the effectiveness of interventions